Clinical analysis of amphotericin B in the treatment of invasive fungal infections in 121 patients with hematologic diseases.
- Author:
Lin JIA
1
;
Mei HUANG
;
Wen-Li LIU
;
Yi-Cheng ZHANG
;
Han-Ying SUN
;
Dong-Hua ZHANG
;
Jin-Niu DENG
;
Jian-Feng ZHOU
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adult; Aged; Amphotericin B; therapeutic use; Antifungal Agents; therapeutic use; Female; Humans; Male; Middle Aged; Mycoses; drug therapy; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2008;29(9):619-622
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the efficacy and safety of amphotericin B for treatment of invasive fungal infections (IFI) in patients with hematologic diseases.
METHODS121 patients were given amphotericin B 5 -50 mg/d for 5 - 101 d with a median of 19 d.
RESULTSThe clinical efficacy rate was 67.3%, and fungal elimination rate 66.7%. The adverse events included rigor and fever, hypokalaemia, hepatic damage, nephrotoxicity, nausea and vomiting, phlebitis and teeter.
CONCLUSIONAmphotericin B is still a high-efficiency drug in the treatment of IFI, although it has many side effects. With monitoring of hepatic and renal function, it is still a relatively safe and effective drug.
